Clinical Trial Results - Progress in Cancer Care
These summaries highlight recently released results from cancer clinical trials. The findings are significant enough that they are likely to influence your medical care.
The summaries are listed in reverse chronological order. You may also use the navigation tools on the left to search the summaries by keyword or type of cancer.
(Posted: 06/07/2012) - A low dose of radioactive iodine given after surgery for thyroid cancer destroyed (ablated) residual thyroid tissue as effectively as a higher dose, with fewer side effects and less exposure to radiation, according to two European randomized controlled trials published May 3, 2012 in the New England Journal of Medicine.
Sigmoidoscopy Proves to Be Effective Screening Tool for Colorectal Cancer
(Posted: 06/07/2012) - In a large randomized trial involving healthy men and women aged 55 to 74, sigmoidoscopy substantially reduced the incidence of and mortality from colorectal cancer.
Chemoradiation May Help Some Patients with Bladder Cancer Avoid Radical Surgery
(Posted: 05/14/2012) - Researchers in the United Kingdom have found that adding chemotherapy to radiation therapy as a treatment for bladder cancer may reduce the risk of a recurrence more than radiation alone, without causing a substantial increase in side effects.
Drug for Multiple Myeloma Demonstrated to Significantly Extend Disease-Free Survival
(Posted: 12/18/2009, Updated: 05/09/2012) - Initial results from a large, randomized clinical trial for patients with multiple myeloma, a cancer of the blood and bone marrow, showed that patients who received the oral drug lenalidomide (Revlimid, also known as CC-5013) following a blood stem cell transplant had their cancer kept in check longer than patients who received a placebo.
Combining Chemotherapy with Bevacizumab Improves Outcomes for Ovarian Cancer Patients
(Posted: 06/29/2011, Updated: 04/25/2012) - Results from two phase III randomized clinical trials suggest that, at least for some patients with ovarian cancer, adding the antiangiogenesis agent bevacizumab to chemotherapy increases the time to disease progression and may improve survival.